Figure 2.

Proportion of all and high-risk subjects achieving targets defined by European guidelines*. A. All Subjects. B. High-Risk Subjects without AVD. Error bars = standard error. * European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) [12]. † Triple combination includes LDL-C <2.5 mmol/L, non-HDL-C <3.3 mmol/L, and Apo B <1.0 g/L. A, atorvastatin (10, 20 or 40 mg); Apo, apolipoprotein; AVD, atherosclerotic vascular disease; E, ezetimibe 10 mg; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.

Constance et al. Lipids in Health and Disease 2014 13:13   doi:10.1186/1476-511X-13-13
Download authors' original image